Dicerna Pharmaceuticals (DRNA) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free DRNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineArrowhead Pharmaceuticals (NASDAQ: ARWR)fool.com - May 25 at 11:01 PM'Mad Money' Lightning Round: I'm Staying Away From Five Belowthestreet.com - February 16 at 10:02 AMBiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News Summarybenzinga.com - February 7 at 7:33 AMMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028marketwatch.com - January 26 at 2:13 PMWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growthfinance.yahoo.com - January 19 at 12:03 AMDRNA Jan 2022 22.500 callca.finance.yahoo.com - January 14 at 10:32 PMDRNA Jul 2022 40.000 call(CONTRca.finance.yahoo.com - January 14 at 10:32 PMNovo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisitionfinance.yahoo.com - December 28 at 1:12 PMmarketbeat.com - December 28 at 6:00 AMDicerna Pharmaceuticals (NASDAQ:DRNA) Receives Buy Rating from SVB Leerinkmarketbeat.com - November 25 at 7:18 AMDICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNAprnewswire.com - November 19 at 11:46 PMSHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.finance.yahoo.com - November 19 at 1:03 AMDICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firmfinance.yahoo.com - November 18 at 3:00 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordiskfinance.yahoo.com - November 18 at 3:00 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.finance.yahoo.com - November 18 at 3:00 PMDicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billionbarrons.com - November 18 at 10:00 AMUPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billionfinance.yahoo.com - November 18 at 10:00 AMmarketbeat.com - November 18 at 6:56 AMDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021finance.yahoo.com - November 12 at 9:28 AMDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lillyfinance.yahoo.com - November 12 at 9:28 AMDicerna Pharmaceuticals's Return On Capital Employed Overviewbenzinga.com - November 10 at 6:05 PMDicerna Pharmaceuticals: Q3 Earnings Snapshotsfgate.com - November 9 at 10:03 AMDicerna Announces Third Quarter 2021 Financial Results and Provides a Business Updatefinance.yahoo.com - November 9 at 10:03 AMDicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021finance.yahoo.com - November 4 at 2:46 PMHedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)finance.yahoo.com - October 18 at 2:25 PMDicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021finance.yahoo.com - October 15 at 6:55 PMDicerna Highlights Will Give Poster Presentations At American Association For Study Of Liver Nov. 12-15, 2021benzinga.com - October 14 at 6:49 PMDicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in Novemberfinance.yahoo.com - October 14 at 6:49 PMDicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorderfinance.yahoo.com - September 28 at 8:29 AMDicerna Announces New Executive Leadership Appointmentsfinance.yahoo.com - September 22 at 8:09 AMWhere Dicerna Pharmaceuticals Stands With Analystsmarkets.businessinsider.com - August 21 at 5:59 PMZacks Investment Research Upgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) to "Hold"marketbeat.com - August 19 at 7:47 PMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are More Bearish Than They Used To Benasdaq.com - August 15 at 3:43 PMDicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $110,500 of Sharesfinance.yahoo.com - August 13 at 4:30 PMIs Dicerna Stock a Buy Right Now? This Is What You Need to Knowfinance.yahoo.com - August 10 at 10:38 PMDicerna Pharmaceuticals, inc (DRNA) Q2 2021 Earnings Call Transcriptfinance.yahoo.com - August 9 at 5:52 PMDicerna Pharmaceuticals: Q2 Earnings Insightsbenzinga.com - August 9 at 7:51 AMDicerna Pharmaceuticals: Q2 Earnings Snapshotsfgate.com - August 9 at 7:51 AMDicerna Announces Second Quarter 2021 Financial Results and Provides a Business Updatefinance.yahoo.com - August 9 at 7:51 AMCitigroup Lowers Dicerna Pharmaceuticals (NASDAQ:DRNA) to Neutralmarketbeat.com - August 9 at 7:09 AMAnalyst Ratings For Dicerna Pharmaceuticalsmarkets.businessinsider.com - August 6 at 2:09 PMDicerna Pharmaceuticals Drops on Mixed Drug-Trial Resultsfinance.yahoo.com - August 6 at 2:09 PMDicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluriafinance.yahoo.com - August 5 at 6:58 PMmarketbeat.com - August 5 at 4:01 PMDicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021finance.yahoo.com - August 2 at 7:05 PMDicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growthfinance.yahoo.com - July 29 at 5:26 PMDicerna posts interim results from early-stage belcesiran liver disease trialseekingalpha.com - July 23 at 8:09 PM Get Dicerna Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. DRNA Media Mentions By Week DRNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRNA News Sentiment▼0.000.42▲Average Medical News Sentiment DRNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRNA Articles This Week▼00▲DRNA Articles Average Week Get Dicerna Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arrowhead Pharmaceuticals News HUTCHMED News IDEAYA Biosciences News Amicus Therapeutics News Xenon Pharmaceuticals News ACADIA Pharmaceuticals News MoonLake Immunotherapeutics News Bausch Health Companies News Axsome Therapeutics News MorphoSys News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRNA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarningsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
